Here is a selection of this week's news from around the world
 |
 |
|
|
FDA rejects Heron, Nabriva drug applications, citing manufacturing concerns Manufacturing issues have tripped up two experimental drugs, resulting in the Food and Drug Administration handing their respective makers Complete Response Letters this week. To read more follow this BioPharmaDive link |
Novo Nordisk’s Victoza found to cut blood sugar in children Novo Nordisk has announced the results of a Phase III diabetes trial in which its Victoza (liraglutide) injection was found to hit both its primary and secondary endpoints, reducing A1C - the amount of haemoglobin in the blood that has glucose attached to it - at both 26 weeks and 52 weeks. To read more follow this PharmaTimes link |
|
 |
 |
|
|
6,000 non-smokers die of lung cancer each year New research published in the journal of the Royal Society of Medicine has found that in the UK an estimated 6,000 non-smokers die of lung cancer every year. To read more follow this PharmaTimes link |
Amid outbreaks, Merck ramps up measles vaccine manufacturing Merck & Co. is making more measles vaccines to serve a growing demand in the U.S., where a series of outbreaks have spurred a decades-high number of measles cases. To read more follow this BioPharmaDive link |
|
 |
 |
|
|
Renewable energy to power all Novo drug production by next year By next year, all of the electricity Novo Nordisk uses to manufacture its medicines will be generated from renewable energy sources, an achievement the Danish drugmaker says will be a first among drugmakers signed up to a climate initiative called RE100. To read more follow this BioPharmaDive link |
Blood samples to help choose early phase clinical trials for cancer patients Cancer Research UK has published research that could help match cancer patients with no other treatment options to clinical trials with experimental medicines. To read more follow this PharmaTimes link |